Holen Sie sich die Stockscreener-App
2.50
3.10%
-0.08
Handel nachbörslich:
2.54
0.04
+1.60%
Schlusskurs vom Vortag:
$2.58
Offen:
$2.58
24-Stunden-Volumen:
19,872
Relative Volume:
0.01
Marktkapitalisierung:
$6.33M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-4.74M
KGV:
-3.3333
EPS:
-0.75
Netto-Cashflow:
$-3.46M
1W Leistung:
-8.09%
1M Leistung:
-11.03%
6M Leistung:
-20.73%
1J Leistung:
-54.71%
1-Tages-Spanne:
$2.40
$2.58
1-Wochen-Bereich:
$2.13
$2.7059
52-Wochen-Spanne:
$2.0202
$12.00
Lipella Pharmaceuticals Inc Stock (LIPO) Company Profile
Firmenname
Lipella Pharmaceuticals Inc
Sektor
Branche
Telefon
412-901-0315
Adresse
400 N LEXINGTON ST, PITTSBURGH
Vergleichen Sie LIPO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LIPO
Lipella Pharmaceuticals Inc
|
2.50 | 6.33M | 0 | -4.74M | -3.46M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 125.55B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 67.78B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 36.24B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.99B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.77B | 3.81B | -644.79M | -669.77M | -6.24 |
Lipella Pharmaceuticals Inc Aktie (LIPO) Neueste Nachrichten
Virtu Financial LLC Acquires Shares of 13,310 Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) - Defense World
Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast - The Globe and Mail
Clinical Trial Success: Lipella's 40-Year Veteran Shares Breakthrough Journey in Exclusive Interview - Stock Titan
Lipella Pharmaceuticals Inc. (LIPO) reports earnings - Quartz
LIPELLA PHARMACEUTICALS INC. SEC 10-K Report - TradingView
Spartan Capital Securities, LLC Proudly Serves as the Sole Agent in Lipella Pharmaceuticals Inc. - Ukraine Business Journal
Spartan Capital Securities, LLC Announces Key February Transactions - The Manila Times
Spartan Capital Securities, LLC Announces Key February Transactions - GlobeNewswire Inc.
Lipella Pharmaceuticals stock hits 52-week low at $2.21 - Investing.com India
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $3,788,000 Private Placement - The Manila Times
Spartan Capital Securities, LLC Serves as Sole Placement - GlobeNewswire
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.’s $3,788,000 Private Placement - Yahoo Finance
Lipella Pharmaceuticals (LIPO) Expected to Announce Earnings on Tuesday - Defense World
FDA approves Lipella's oral treatment access program - MSN
Lipella Pharmaceuticals modifies agreement with Spartan Capital By Investing.com - Investing.com South Africa
Lipella Pharmaceuticals modifies agreement with Spartan Capital - Investing.com
With New Data, Lipella Plots 2025 Milestones For Oral Rinse Tacrolimus - News & Insights
Analyzing Lipella Pharmaceuticals (NASDAQ:LIPO) and IDEAYA Biosciences (NASDAQ:IDYA) - Defense World
Lipella Pharmaceuticals Gains Buy Rating from Jason McCarthy Following Positive Phase 2a Results for LP-310 - TipRanks
3 Penny Stocks to Watch Now, 2/13/25 - TipRanks
Lipella Pharmaceuticals Announces Positive Phase 2a Results for LP-310 in Oral Lichen Planus Treatment - Defense World
Biotech Rips On Topline Analysis - The Globe and Mail
Nano Cap Lipella Pharmaceuticals Stock Jumps On Positive Trial Data In Patients With Sore Mouth Membranes - AOL.com
Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus - GlobeNewswire
Lipella Pharmaceuticals Shares Rise After Positive Phase 2a Trial Results for Oral Lichen Planus Treatment - Marketscreener.com
Stock market news: Firefly Neuroscience +214.56%, Dominari Holdings +37.66% among top gainers during midday trading - Business Upturn
Stock market today: Firefly Neuroscience +60.32%, Dominari Holdings +36.36% among top gainers in early trading - Business Upturn
Lipella Pharmaceuticals Gains FDA Approval for LP-310 - TipRanks
Lipella Pharmaceuticals (LIPO) Stock Soars In Pre-Hour Session - Stocks Telegraph
Clinical Trials News Live Feed - StockTitan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
How Did Markets React to the Latest Round of Tariff Announcements? - The Globe and Mail
Clinical Trial Success: Lipella's LP-310 Slashes Pain Scores by 64% in Oral Disease Study - StockTitan
Top Small Cap Stocks To Watch NowFebruary 06th - MarketBeat
Lipella Pharmaceuticals Inc (LIPO) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - The InvestChronicle
Taking on analysts’ expectations and winning: Lipella Pharmaceuticals Inc (LIPO) - SETE News
These 5 Health Care Stocks Saw The Sharpest Retail Interest Jump Last Week - Asianet Newsable
Analyzing the Price-to-Earnings Ratio of Lipella Pharmaceuticals Inc (LIPO) - The News Heater
🔬 Latest pharma industry updates 👇 - substack.com
Stock summary: Lipella Pharmaceuticals posted weekly surge of 13.70% as it got FDA approval for an expanded access program - Business Upturn
LIPO Stock Sees Surge of Approximately 74.16% in Last Five Days - Knox Daily
Is Lipella Pharmaceuticals Inc (NASDAQ:LIPO) stock a better investment at this time? - US Post News
Lipella Pharmaceuticals Receives Buy Rating Amidst Promising FDA Approval and Strategic Financial Moves - TipRanks
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Lipella Pharmaceuticals Inc [LIPO] Revenue clocked in at $0.48 million, up 52.46% YTD: What’s Next? - The DBT News
FDA approves Lipella’s oral treatment access program By Investing.com - Investing.com Nigeria
Lipella Pharmaceuticals skyrockets on FDA access approval for mouth disease treatment - Mugglehead
United States shares mixed at close of trade; Dow Jones Industrial Average down 0.28% - Investing.com India
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.28% - Investing.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Offerings News Live Feed - StockTitan
Finanzdaten der Lipella Pharmaceuticals Inc-Aktie (LIPO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.23%
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):